3513659337

234

Maxwell. P.H., C.W. Pugh, and P.J. Ratcliffe. 2001. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 11:293-299.

Mayer, G., G. Boileau, and M. Bendayan. 2003. Furin interacts with proMTl-MMP and integrin alphaV at specialized domains of renal celi plasma membranę. J Celi Sci. 116:1763-1773.

McCarty. M.F., and J. Whitaker. 2010. Manipulating tumor acidification as a cancer treatment strategy. Alternative medicine review : a joumal of clinical therapeutic. 15:264-272.

McMahon, S., F. Grondin, P.P. McDonald, D.E. Richard, and C.M. Dubois. 2005. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem. 280:6561-6569.

McMahon, S., M.H. Laprise, and C.M. Dubois. 2003. Altcmative pathway for the role of furin in tumor celi invasion process. Enhanced MMP-2 levels through bioactive TGFbeta. Exp Celi Res. 291:326-339.

Md Hashim, N.F., N.S. Nicholas, A.E. Dart, S. Kiriakidis, E. Paleolog, and C.M. Wells. 2013. Hypoxia-induced invadopodia formation: a role for beta-P!X. Open biologw 3:120159.

Mellman, 1. 1992. The importance of being acid: the role of acidification in intracellular membranę traffic. J Exp Biol. 172:39-45.

Mellman, I., R. Fuchs, and A. Helenius. 1986. Acidification of the endocytic and exocytic pathways. Annual review of biocliemistry. 55:663-700.

Menetrey, J., D. Gillet, and A. Menez. 2005. Structural features common to intracellularly acting toxins from bacteria. Toxicon. 45:129-137.

Mcre, J., J. Morlon-Guyot, A. Bonhoure, L. Chichę, and B. Beaumelle. 2005. Acid-triggered membranę insertion of Pseudomonas exotoxin A invoIves an original mechanism based on pH-regulated tryptophan exposure. J Biol Chem. 280:21194-21201.

Miguel, D.C., J.K. Yokoyama-Yasunaka, W.K. Andreoli, R.A. Mortara, and S.R. Uliana. 2007. Tamoxifen is effective against Leishmania and induces a rapid alkalinizalion of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother. 60:526-534.

Minucci, S., and P.G. Pelicci. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and morę) treatments for cancer. Nar Rev Cancer. 6:38-51.

Mitsiades, C.S., N.S. Mitsiades, C.J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, C. Bailey, M. Joseph, T.A. Libermann, V.M. Richon, P.A. Marks, and K.C. Anderson. 2004. Transcriptional signaturc of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 101:540-545.

Miyazono, K., U. Hellman, C. Wernstedt, and C.H. Heldin. 1988. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem. 263:6407-6415.

Mizutani, K., H. Miki, H. He, H. Maruta, and T. Takenawa. 2002. Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer Res. 62:669-674.